Tech Company Financing Transactions
ParcelBio Funding Round
On 5/7/2026, ParcelBio raised $13 million in Seed funding from Breyer Capital, General Catalyst and Metaplanet.
Transaction Overview
Company Name
Announced On
5/7/2026
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to support development of its proprietary APEXm (Amplified and Prolonged EXpression mRNA) platform and advance its pipeline, including its lead in vivo CAR-T program for autoimmune disease, as well as additional programs in oncology and encoded protein therapeutics.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
135 Mississippi St
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Undisclosed
Website
Email Address
Overview
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm� platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Weinberg
Chief Scientific Officer
Chris Carlson
Browse more venture capital transactions:
Prev: 5/7/2026: Ethos venture capital transaction
Next: 5/7/2026: RAMP venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs